A Novel Inflammatory lncRNAs Prognostic Signature for Predicting the Prognosis of Low-Grade Glioma Patients

BackgroundAs immunotherapy has received attention as new treatments for brain cancer, the role of inflammation in the process of glioma is of particular importance. Increasing studies have further shown that long non-coding RNAs (lncRNAs) are important factors that promote the development of glioma....

Full description

Bibliographic Details
Main Authors: Zijin Xiang, Xueru Chen, Qiaoli Lv, Xiangdong Peng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Genetics
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2021.697819/full
_version_ 1818364870200918016
author Zijin Xiang
Xueru Chen
Qiaoli Lv
Xiangdong Peng
author_facet Zijin Xiang
Xueru Chen
Qiaoli Lv
Xiangdong Peng
author_sort Zijin Xiang
collection DOAJ
description BackgroundAs immunotherapy has received attention as new treatments for brain cancer, the role of inflammation in the process of glioma is of particular importance. Increasing studies have further shown that long non-coding RNAs (lncRNAs) are important factors that promote the development of glioma. However, the relationship between inflammation-related lncRNAs and the prognosis of glioma patients remains unclear. The purpose of this study is to construct and validate an inflammation-related lncRNA prognostic signature to predict the prognosis of low-grade glioma patients.MethodsBy downloading and analyzing the gene expression data and clinical information of the Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) patients with low-grade gliomas, we could screen for inflammatory gene-related lncRNAs. Furthermore, through Cox and the Least Absolute Shrinkage and Selection Operator regression analyses, we established a risk model and divided patients into high- and low-risk groups based on the median value of the risk score to analyze the prognosis. In addition, we analyzed the tumor mutation burden (TMB) between the two groups based on somatic mutation data, and explored the difference in copy number variations (CNVs) based on the GISTIC algorithm. Finally, we used the MCPCounter algorithm to study the relationship between the risk model and immune cell infiltration, and used gene set enrichment analysis (GSEA), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses to explore the enrichment pathways and biological processes of differentially expressed genes between the high- and low-risk groups.ResultsA novel prognostic signature was constructed including 11 inflammatory lncRNAs. This risk model could be an independent prognostic predictor. The patients in the high-risk group had a poor prognosis. There were significant differences in TMB and CNVs for patients in the high- and low-risk groups. In the high-risk group, the immune system was activated more significantly, and the expression of immune checkpoint-related genes was also higher. The GSEA, GO, and KEGG analyses showed that highly expressed genes in the high-risk group were enriched in immune-related processes, while lowly expressed genes were enriched in neuromodulation processes.ConclusionThe risk model of 11 inflammation-related lncRNAs can serve as a promising prognostic biomarker for low-grade gliomas patients.
first_indexed 2024-12-13T22:11:14Z
format Article
id doaj.art-b5af29dd7ed4404196d047b09b448d56
institution Directory Open Access Journal
issn 1664-8021
language English
last_indexed 2024-12-13T22:11:14Z
publishDate 2021-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Genetics
spelling doaj.art-b5af29dd7ed4404196d047b09b448d562022-12-21T23:29:43ZengFrontiers Media S.A.Frontiers in Genetics1664-80212021-08-011210.3389/fgene.2021.697819697819A Novel Inflammatory lncRNAs Prognostic Signature for Predicting the Prognosis of Low-Grade Glioma PatientsZijin Xiang0Xueru Chen1Qiaoli Lv2Xiangdong Peng3Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, ChinaJiangxi Key Laboratory of Translational Cancer Research, Jiangxi Cancer Hospital of Nanchang University, Nanchang, ChinaDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, ChinaBackgroundAs immunotherapy has received attention as new treatments for brain cancer, the role of inflammation in the process of glioma is of particular importance. Increasing studies have further shown that long non-coding RNAs (lncRNAs) are important factors that promote the development of glioma. However, the relationship between inflammation-related lncRNAs and the prognosis of glioma patients remains unclear. The purpose of this study is to construct and validate an inflammation-related lncRNA prognostic signature to predict the prognosis of low-grade glioma patients.MethodsBy downloading and analyzing the gene expression data and clinical information of the Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) patients with low-grade gliomas, we could screen for inflammatory gene-related lncRNAs. Furthermore, through Cox and the Least Absolute Shrinkage and Selection Operator regression analyses, we established a risk model and divided patients into high- and low-risk groups based on the median value of the risk score to analyze the prognosis. In addition, we analyzed the tumor mutation burden (TMB) between the two groups based on somatic mutation data, and explored the difference in copy number variations (CNVs) based on the GISTIC algorithm. Finally, we used the MCPCounter algorithm to study the relationship between the risk model and immune cell infiltration, and used gene set enrichment analysis (GSEA), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses to explore the enrichment pathways and biological processes of differentially expressed genes between the high- and low-risk groups.ResultsA novel prognostic signature was constructed including 11 inflammatory lncRNAs. This risk model could be an independent prognostic predictor. The patients in the high-risk group had a poor prognosis. There were significant differences in TMB and CNVs for patients in the high- and low-risk groups. In the high-risk group, the immune system was activated more significantly, and the expression of immune checkpoint-related genes was also higher. The GSEA, GO, and KEGG analyses showed that highly expressed genes in the high-risk group were enriched in immune-related processes, while lowly expressed genes were enriched in neuromodulation processes.ConclusionThe risk model of 11 inflammation-related lncRNAs can serve as a promising prognostic biomarker for low-grade gliomas patients.https://www.frontiersin.org/articles/10.3389/fgene.2021.697819/fullgliomalncRNAinflammationimmunityprognosis
spellingShingle Zijin Xiang
Xueru Chen
Qiaoli Lv
Xiangdong Peng
A Novel Inflammatory lncRNAs Prognostic Signature for Predicting the Prognosis of Low-Grade Glioma Patients
Frontiers in Genetics
glioma
lncRNA
inflammation
immunity
prognosis
title A Novel Inflammatory lncRNAs Prognostic Signature for Predicting the Prognosis of Low-Grade Glioma Patients
title_full A Novel Inflammatory lncRNAs Prognostic Signature for Predicting the Prognosis of Low-Grade Glioma Patients
title_fullStr A Novel Inflammatory lncRNAs Prognostic Signature for Predicting the Prognosis of Low-Grade Glioma Patients
title_full_unstemmed A Novel Inflammatory lncRNAs Prognostic Signature for Predicting the Prognosis of Low-Grade Glioma Patients
title_short A Novel Inflammatory lncRNAs Prognostic Signature for Predicting the Prognosis of Low-Grade Glioma Patients
title_sort novel inflammatory lncrnas prognostic signature for predicting the prognosis of low grade glioma patients
topic glioma
lncRNA
inflammation
immunity
prognosis
url https://www.frontiersin.org/articles/10.3389/fgene.2021.697819/full
work_keys_str_mv AT zijinxiang anovelinflammatorylncrnasprognosticsignatureforpredictingtheprognosisoflowgradegliomapatients
AT xueruchen anovelinflammatorylncrnasprognosticsignatureforpredictingtheprognosisoflowgradegliomapatients
AT qiaolilv anovelinflammatorylncrnasprognosticsignatureforpredictingtheprognosisoflowgradegliomapatients
AT xiangdongpeng anovelinflammatorylncrnasprognosticsignatureforpredictingtheprognosisoflowgradegliomapatients
AT zijinxiang novelinflammatorylncrnasprognosticsignatureforpredictingtheprognosisoflowgradegliomapatients
AT xueruchen novelinflammatorylncrnasprognosticsignatureforpredictingtheprognosisoflowgradegliomapatients
AT qiaolilv novelinflammatorylncrnasprognosticsignatureforpredictingtheprognosisoflowgradegliomapatients
AT xiangdongpeng novelinflammatorylncrnasprognosticsignatureforpredictingtheprognosisoflowgradegliomapatients